<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Vinall, Maria</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Peuskens, Joseph</style></author><author><style face="normal" font="default" size="100%">Falkai, Peter</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Quetiapine for the Treatment of Schizophrenia—Selected Posters</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2008</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2008-10-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">14-14</style></pages><abstract><style  face="normal" font="default" size="100%">Schizophrenia accounts for a significant portion of the global burden of neuropsychiatric disorders. It is often refractory to treatment and relapse due to poor adherence is also common. In addition, treatments for schizophrenia are frequently associated with side effects that can cause serious medical problems, such as cardiovascular disease. Quetiapine is approved for the treatment of schizophrenia and impacts a broad range of symptoms that affect quality of life.</style></abstract><number><style face="normal" font="default" size="100%">3</style></number><volume><style face="normal" font="default" size="100%">8</style></volume></record></records></xml>